Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | May 20, 2020 | May 23, 2020 |
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director | May 18, 2022 | May 20, 2022 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 02, 2026 | June 04, 2026 |
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | June 12, 2025 | June 16, 2025 |
| EXICURE, INC.XCUR · Entity 8068 | Director | June 02, 2021 | June 04, 2021 |
| Kardigan, Inc.KARD · Entity 4569 | Director | June 17, 2026 | June 22, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director | August 06, 2026 | August 07, 2026 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 09, 2025 | June 10, 2025 |
| XOMA Royalty CorpXOMA · Entity 30207 | Director | February 10, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date May 20, 2020 · Filed May 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,143 |
Reported balance
After 2020-05-20 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 49,143 · Balance 49,143 F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | Direct | 211,111 |
Reported balance
After 2020-05-20 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-05-20 · Grant · Acquired 211,111 · Balance 211,111 F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit.
F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings.
F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date.
Aurinia Pharmaceuticals Inc.
Report date May 18, 2022 · Filed May 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,733 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 8,733 · Balance 8,733 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.45 · Expires 2032-05-18 | Direct | 14,612 |
Reported balance
After 2022-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-18 · Grant · Acquired 14,612 · Balance 14,612 F2: The option vests in twelve equal monthly installments commencing on June 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.
F2: The option vests in twelve equal monthly installments commencing on June 18, 2022.
BIOMARIN PHARMACEUTICAL INC
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,270 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 17,270 F1: Restricted stock units granted on June 2, 2026. Price not applicable. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Prairie Capital Ventures LLC | 416 |
Reported balance
Holding disclosure · report date 2026-06-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 416 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 2, 2026. Price not applicable.
Century Therapeutics, Inc.
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-06-12 | Direct | 44,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 44,000 · Balance 44,000 F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
EXICURE, INC.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2031-06-01 | Direct | 50,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.
Kardigan, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,706 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-06-16 | Direct | 57,573 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 57,573 · Balance 57,573 F2: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from June 17, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.
F2: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from June 17, 2026, subject to the Reporting Person's continued service on each such vesting date.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2034-10-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-02-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Sagimet Biosciences Inc.
Report date June 09, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2035-06-08 | Direct | 32,250 |
Reported balance
After 2025-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-09 · Grant · Acquired 32,250 · Balance 32,250 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date.
XOMA Royalty Corp
Report date February 10, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2027-02-10 | Direct | 8,000 |
Reported balance
After 2017-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-10 · Grant · Acquired 8,000 · Balance 8,000 F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017.
F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 616,772 · Balance 0 F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 107,739 · Balance 0 F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F3: The Ordinary Shares are held by the Timothy P. Walbert 2021 Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 100,300 · Balance 0 F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F4: The Ordinary Shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 49,935 · Balance 0 F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-22 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 742,565 · Balance 0 F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F5: The Option (as defined in footnote 6 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-03-22 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 1,650,000 · Balance 0 F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F5: The Option (as defined in footnote 6 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-10-06 · Disposition to issuer · Disposed 34,929 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F8: The Ordinary Shares subject to the RSUs vest on January 5, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-10-06 · Disposition to issuer · Disposed 49,198 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-10-06 · Disposition to issuer · Disposed 71,290 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-10-06 · Disposition to issuer · Disposed 45,843 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-10-06 · Disposition to issuer · Disposed 17,448 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-10-06 · Disposition to issuer · Disposed 104,786 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-10-06 · Disposition to issuer · Disposed 14,759 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-10-06 · Disposition to issuer · Disposed 44,278 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-10-06 · Disposition to issuer · Disposed 73,798 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-10-06 · Disposition to issuer · Disposed 35,645 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-10-06 · Disposition to issuer · Disposed 17,823 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-10-06 · Disposition to issuer · Disposed 17,823 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-10-06 · Disposition to issuer · Disposed 4,657 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-10-06 · Disposition to issuer · Disposed 14,283 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-10-06 · Disposition to issuer · Disposed 20,697 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2023-10-06 · Disposition to issuer · Disposed 21,426 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2023-10-06 · Disposition to issuer · Disposed 12,854 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2023-10-06 · Disposition to issuer · Disposed 4,285 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2023-10-06 · Disposition to issuer · Disposed 10,349 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2023-10-06 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program.
F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F3: The Ordinary Shares are held by the Timothy P. Walbert 2021 Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary.
F4: The Ordinary Shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants.
F5: The Option (as defined in footnote 6 to this Form 4) is fully vested.
F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F8: The Ordinary Shares subject to the RSUs vest on January 5, 2024.
F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.
F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.
F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.
F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 5,130 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Zyla Life Sciences
Report date May 20, 2020 · Filed May 21, 2020
Section 16 reporting ended · disclosed 2020-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Disposition to issuer · Disposed 26,953 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2022 Filed Jan 6, 2022 20:56 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 152,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002282 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,128 F2 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2022, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 20:56 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 241,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002282 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 20:56 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 21,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002282 · doc4.xml · derivative · entry 9 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 21,424 Underlying: Ordinary Shares · 21,424 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 20:56 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 73,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002282 · doc4.xml · derivative · entry 8 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,796 Underlying: Ordinary Shares · 73,796 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-22-000943 · doc4.xml · derivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017,565 Underlying: Ordinary Shares · 25,000 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 7,522 | $108.55 | $816,513.10 |
DisclosureSEC source: 0001209191-22-000943 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.47 to $109.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 67,478 | $108.02 | $7,288,973.56 |
DisclosureSEC source: 0001209191-22-000943 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,004 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.475 to $108.465 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 25,000 | $22.14 | $553,500.00 |
DisclosureSEC source: 0001209191-22-000943 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 17:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 13,487 | $103.54 | $1,396,443.98 |
DisclosureSEC source: 0001209191-21-067322 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.285 to $103.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 17:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 15,875 | $102.62 | $1,629,092.50 |
DisclosureSEC source: 0001209191-21-067322 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,969 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.16 to $103.065 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 17:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 20,638 | $101.48 | $2,094,344.24 |
DisclosureSEC source: 0001209191-21-067322 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,844 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.13 to $102.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 637 | $120.09 | $76,497.33 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,482 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.99 to $120.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 9,733 | $119.36 | $1,161,730.88 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,119 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.985 to $119.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 6,829 | $118.46 | $808,963.34 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,852 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.99 to $118.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 7,801 | $117.31 | $915,135.31 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,681 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.96 to $117.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 100,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,300 F1 · ownership.nature: The shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 100,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062705 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 31,196 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 600 | $112.01 | $67,206.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,482 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 18,940 | $110.80 | $2,098,552.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,082 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.48 to $111.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 30,460 | $109.96 | $3,349,381.60 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,022 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.48 to $110.47 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 110,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 131,496 Read SEC document |
| September 17, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 110,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,482 Read SEC document |
| September 17, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 107,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 107,739 F1 · ownership.nature: The shares are held by the Timothy P. Walbert Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary. Read SEC document |
| September 17, 2021 Filed Oct 1, 2021 16:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 107,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058424 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,984 Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,435 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-21-053645 · doc4.xml · derivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,565 Underlying: Ordinary Shares · 7,435 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 7,435 | $22.14 | $164,610.90 |
DisclosureSEC source: 0001209191-21-053645 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,434 | $102.57 | $249,655.38 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,288 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.33 to $102.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 22,566 | $101.65 | $2,293,833.90 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,722 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.09 to $102.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 69,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · derivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,668 Underlying: Ordinary Shares · 69,668 shares Expires not disclosed F5 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 15,432 | $102.50 | $1,581,780.00 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,288 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 34,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,720 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| July 08, 2021 Filed Jul 30, 2021 16:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048792 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,887 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,408 | $94.78 | $133,450.24 |
DisclosureSEC source: 0001209191-21-045058 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,887 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.51 to $94.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 23,592 | $93.80 | $2,212,929.60 |
DisclosureSEC source: 0001209191-21-045058 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,295 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.42 to $94.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:22 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 31,347 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001628280-21-012388 · wf-form4_162389292098153.xml · derivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,347 Underlying: Common Shares · 31,347 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on July 14, 2021. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:22 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-21-038327 · doc4.xml · derivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 17,524 | $92.21 | $1,615,888.04 |
DisclosureSEC source: 0001209191-21-037688 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,887 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.75 to $92.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 7,476 | $91.00 | $680,316.00 |
DisclosureSEC source: 0001209191-21-037688 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,411 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.48 to $91.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 19:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 20,872 | $95.14 | $1,985,762.08 |
DisclosureSEC source: 0001209191-21-029368 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,838 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.58 to $95.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 19:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 4,128 | $94.15 | $388,651.20 |
DisclosureSEC source: 0001209191-21-029368 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.425 to $94.35 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:44 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,312 | $91.98 | $212,649.21 |
DisclosureSEC source: 0001209191-21-016907 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,838 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.83 to $92.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:44 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 24,663 | $91.29 | $2,251,487.74 |
DisclosureSEC source: 0001209191-21-016907 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.83 to $91.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 69,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012406 · doc4.xml · derivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,666 Underlying: Ordinary Shares · 69,666 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 18,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012406 · doc4.xml · derivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,868 Underlying: Ordinary Shares · 18,868 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,179 | $87.17 | $364,283.43 |
DisclosureSEC source: 0001209191-21-012406 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,813 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 9,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012406 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,992 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 9,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007369 · doc4.xml · derivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 9,087 Underlying: Ordinary Shares · 9,087 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3 annually on each anniversary of February 1, 2019 (the grant date). F2 · derivative.expiration_date: The RSU's vest 1/3 annually on each anniversary of February 1, 2019 (the grant date). Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,950 | $77.04 | $227,268.00 |
DisclosureSEC source: 0001209191-21-007369 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 19,945 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 9,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007369 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 22,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 20:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 3,871 | $76.90 | $297,692.29 |
DisclosureSEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,559 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.79 to $77.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.